A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type Save

Date Added
February 27th, 2018
PRO Number
Pro00075084
Researcher
Olga Brawman-mintzer

List of Studies

Silhouette
Keywords
Alzheimers
Summary

Evaluate the long-term safety and maintenance of efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type in Veterans at the Ralph H. Johnson VA Medical Center in Charleston, SC.

Inclusion in this study requires successful completion of studies 15-AVP-786-301, 15-AVP-786-302, 17-AVP-786-305 or 12-AVR-131 and a reliable caregiver who is able and willing to comply with all required study procedures.

Institution
MUSC
Recruitment Contact
Keaveny Donovan
843-577-5011 ext 5188
keaveny.donovan@va.gov

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hybrobromide [d6-DM]/quindine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type. Save

Date Added
March 28th, 2017
PRO Number
Pro00064742
Researcher
Olga Brawman-mintzer

List of Studies

Silhouette
Keywords
Alzheimers
Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer's type.

Institution
MUSC
Recruitment Contact
Keaveny Donovan
843-577-5011,extension 5188
keaveny.donovan@va.gov

Change_preferences

-- OR --

Create_login